Evolent Capital Surpluse from 2010 to 2025

EVH Stock  USD 9.33  0.35  3.62%   
Evolent Health's Capital Surpluse is increasing with slightly volatile movements from year to year. Capital Surpluse is predicted to flatten to about 1.1 B. For the period between 2010 and 2025, Evolent Health, Capital Surpluse quarterly trend regression had mean deviation of  449,109,454 and range of 1.4 B. View All Fundamentals
 
Capital Surpluse  
First Reported
2015-06-30
Previous Quarter
1.8 B
Current Value
1.8 B
Quarterly Volatility
421.2 M
 
Yuan Drop
 
Covid
Check Evolent Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evolent Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 124.3 M, Total Revenue of 2.7 B or Gross Profit of 226.2 M, as well as many indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.0163 or PTB Ratio of 1.35. Evolent financial statements analysis is a perfect complement when working with Evolent Health Valuation or Volatility modules.
  
Check out the analysis of Evolent Health Correlation against competitors.
For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.

Latest Evolent Health's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Evolent Health over the last few years. It is Evolent Health's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evolent Health's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Evolent Capital Surpluse Regression Statistics

Arithmetic Mean885,786,233
Geometric Mean735,670,685
Coefficient Of Variation56.76
Mean Deviation449,109,454
Median1,093,174,000
Standard Deviation502,808,201
Sample Variance252816.1T
Range1.4B
R-Value0.92
Mean Square Error43477.9T
R-Squared0.84
Slope96,764,578
Total Sum of Squares3792241.3T

Evolent Capital Surpluse History

20251.1 B
20241.7 B
20221.5 B
20211.3 B
20201.2 B
20191.2 B
20181.1 B

About Evolent Health Financial Statements

Investors use fundamental indicators, such as Evolent Health's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Evolent Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Capital Surpluse1.7 B1.1 B

Currently Active Assets on Macroaxis

When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:
Check out the analysis of Evolent Health Correlation against competitors.
For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.82)
Revenue Per Share
22.277
Quarterly Revenue Growth
0.163
Return On Assets
0.0006
Return On Equity
(0.05)
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.